Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cann Group ( (AU:CAN) ) has shared an update.
Cann Group Limited announced the outcomes of a pilot clinical trial investigating medicinal cannabis as a treatment for Tourette syndrome in adolescents. Conducted by the Murdoch Children’s Research Institute and the Royal Children’s Hospital, the trial showed preliminary evidence supporting the efficacy and safety of medicinal cannabis, with high levels of acceptability reported by parents. The study suggests the feasibility of using medicinal cannabis for Tourette syndrome, recommending further research with a larger cohort to confirm these findings.
More about Cann Group
Cann Group Limited is a company focused on enhancing patients’ lives through the development, production, and supply of innovative cannabis medicines. Based in Melbourne, Australia, the company operates a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group offers a variety of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, serving customers both domestically and internationally. The company also owns Satipharm, known for its patent-protected capsule technology.
YTD Price Performance: 80.0%
Average Trading Volume: 300
Technical Sentiment Signal: Buy
Current Market Cap: $6.2M
See more insights into CAN stock on TipRanks’ Stock Analysis page.